Internalization fraction of the commonly used PSMA-RL in prostate cancer cells, based on in vitro cell experiments, seems to be as low as 10–20% [17]. Thus, relatively short-lived radionuclides like astatine-211 and lead-212 may have an advantage over lutetium-177 and actinium-225 labeled...
177Lu-octreotate is an FDA-approved radionuclide therapy for patients with gastroenteropancreatic neuroendocrine tumours (NETs) expressing somatostatin receptors. The 177Lu-octreotate therapy has shown promising results in clinical trials by prolonging p
The use of radionuclide materials for animal treating is one of the new directions of veterinary medicine. A new technological process for obtaining Lutetium trichloride-177 has been developed for medical purposes, with the use of registration information system, documentation and the life cycle mainte...
In case of low specific activity of the [177Lu]LuCl3 (i.e., > 25 µg total lutetium mass, in case of production via the carrier added route), the amount of HA-DOTATATE peptide was increased up to 500 µg to ensure adequate binding of 177Lu to the peptide. This resulted ...
Isotopia USA and E Solutions have signed commitments to design-build its state-of-the-art GMP manufacturing center.
European Journal of Nuclear Medicine & Molecular ImagingGrunberg J, Lindenblatt D, Dorrer H, Cohrs S, Zhernosekov K, Koster U, et al. Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model. Eur J Nucl Med ...
Lutetium-177 is increasingly used in patients for receptor-targeted radionuclide therapy with peptides such as [DOTA0,Tyr3]octreotate. In our therapy facil... WH Bakker,WAP Breeman,DJ Kwekkeboom,... - The quarterly journal of nuclear medicine and molecular imaging: official publication of the...
Composite outcome measures such as progression-free survival and disease-free survival are increasingly used as surrogate end points in oncology research, frequently serving as the primary end point of pivotal trials that form the basis for FDA and EMA approvals. Such outcome measures combine two or...
The first patient has been dosed in a phase II study investigating the safety and tolerability of the novel agent LiPlaCis for the treatment of advanced or refractory prostate cancer.
One of these therapy practices is avatar therapy (inside), when the client engages in Global medicine immersive sessions while getting together with an avatar representing their particular primary persistent auditory verbal hallucination. The aim of this study was to perform an unsupervised machine-...